2017 ASCO Annual Meeting

Mark E. Robson, MD, Memorial Sloan-Kettering Cancer Center, presenting Abstract LBA4, OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm), during Plenary Press Briefing

Chicago, IL - 2017 ASCO Annual Meeting - Mark E. Robson, MD, Memorial Sloan-Kettering Cancer Center, presenting Abstract LBA4, OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm), during Plenary Press Briefing at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Sunday, June 4, 2017. Approximately 40,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 53rd Annual Meeting, which is being held at McCormick Place. The ASCO Annual Meeting highlights the latest findings in all major areas of oncology, from basic to clinical and epidemiological studies. Photo by © ASCO/Scott Morgan 2017 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org